爱康医疗2024年归母净利润2.74亿元，较去年增加50.4%
3月27日，爱康医疗（01789）发布截至2024年12月31日止年度的业绩公告。公司实现收入约13.46亿元，较2023年同期显著增长23.1%。毛利达到约8.08亿元，增长19.8%。本公司权益股东溢利为2.74亿元，较去年增加50.4%。溢利增长主要归因于收入增加和费用管控的有效性。每股盈利方面，基本每股盈利为0.25元，摊薄每股盈利为0.24元。
在管理层讨论与分析中提到，带量采购政策的实施促进了公司产品的手术量需求持续增长，进而提升了在医院的覆盖率。公司通过积极的市场开拓，尤其是在数字骨科全流程解决方案的带动下，海外手术量和收入均显著增加。值得注意的是，脊柱和创伤内植入物产品的收入增长较为平稳，反映出市场的稳定需求。
从业务分部来看，髋膝关节植入物的销售表现尤为突出，收入同比增长25.8%，而脊柱与创伤植入物的收入则小幅增长3.3%。数字骨科定制产品及服务的收入保持稳定，增长约3.5%。整体来看，公司在市场拓展和产品创新方面表现积极，未来有望持续推动收入增长。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Most Discussed
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10